This study reported two cases of Thai cancer patients, including a 36-year-old female with thyroid cancer of more than 5 years and a 64-year-old male with lung and colon cancers of more than 10 years. The written informed consent was provided for autologous natural killer (NK) cell infusion at the anti-ageing and regenerative medicines clinic. Briefly, the blood was taken from the patient for NK cell count and their cytotoxic activity. Then, the patient’s NK cells were expanded in vitro , characterized and then counted before being delivered to the same patient by a single intravenous infusion. The vital signs and general physical examinations were observed for 2 - 6 hours after the infusion. The patients were discharged if there were no adverse effects. The data showed the increasing number of NK cells and level of cytotoxic activity after the NK cell treatment, compared to the pre-treatment. In addition, the increasing total live cell concentration, as identified by the high percentage of CD56 dim /CD16 bright cytotoxic NK cells, at day 21 of the NK cell expansion was consistent with the increasing cytotoxic activity of the patients after the treatment. Here, we demonstrated that this autologous NK cell therapy might be feasible; however, the study did not aim to evaluate the anti-cancer effect.
Freud, A.G., et al. (2017) The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity, 47, 820-833. https://doi.org/10.1016/j.immuni.2017.10.008
Bjorkstrom, N.K., Ljunggren, H.G. and Michaelsson, J. (2016) Emerging Insights into Natural Killer Cells in Human Peripheral Tissues. Nature Reviews Immunology, 16, 310-320. https://doi.org/10.1038/nri.2016.34
Abel, A.M., et al. (2018) Natural Killer Cells: Development, Maturation, and Clinical Utilization. Frontiers in Immunology, 9, 1869. https://doi.org/10.3389/fimmu.2018.01869
Kiessling, R., Klein, E. and Wigzell, H. (1975) Natural Killer Cells in the Mouse. I. Cytotoxic Cells with Specificity for Mouse Moloney Leukemia Cells. Specificity and Distribution according to Genotype. European Journal of Immunology, 5, 112-117. https://doi.org/10.1002/eji.1830050208
Lanier, L.L., et al. (1986) Natural Killer Cells: Definition of a Cell Type Rather than a Function. The Journal of Immunology, 137, 2735-2739.
Herberman, R.B., Nunn, M.E. and Lavrin, D.H. (1975) Natural Cytotoxic Reactivity of Mouse Lymphoid Cells against Syngeneic Acid Allogeneic Tumors. I. Distribution of Reactivity and Specificity. International Journal of Cancer, 16, 216-229. https://doi.org/10.1002/ijc.2910160204
Ruggeri, L., et al. (1999) Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation. Blood, 94, 333-339. https://doi.org/10.1182/blood.V94.1.333.413a31_333_339
Ruggeri, L., et al. (2002) Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants. Science, 295, 2097-2100. https://doi.org/10.1126/science.1068440
Miller, J.S., et al. (2005) Successful Adoptive Transfer and in Vivo Expansion of Human Haploidentical NK Cells in Patients with Cancer. Blood, 105, 3051-3057. https://doi.org/10.1182/blood-2004-07-2974
Gras Navarro, A., et al. (2014) NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage to Efficiently Kill Glioblastoma and Prolong Animal Survival. The Journal of Immunology, 193, 6192-6206. https://doi.org/10.4049/jimmunol.1400859
Veluchamy, J.P., et al. (2017) In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Frontiers in Immunology, 8, 87. https://doi.org/10.3389/fimmu.2017.00087
Geller, M.A., et al. (2013) Intraperitoneal Delivery of Human Natural Killer Cells for Treatment of Ovarian Cancer in a Mouse Xenograft Model. Cytotherapy, 15, 1297-1306. https://doi.org/10.1016/j.jcyt.2013.05.022
Lee, S.J., et al. (2015) Natural Killer (NK) Cells Inhibit Systemic Metastasis of Glioblastoma Cells and Have Therapeutic Effects against Glioblastomas in the Brain. BMC Cancer, 15, 1011. https://doi.org/10.1186/s12885-015-2034-y
Sakamoto, N., et al. (2015) Phase I Clinical Trial of Autologous NK Cell Therapy Using Novel Expansion Method in Patients with Advanced Digestive Cancer. Journal of Translational Medicine, 13, 277. https://doi.org/10.1186/s12967-015-0632-8
Rubnitz, J.E., et al. (2010) NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 28, 955-959. https://doi.org/10.1200/JCO.2009.24.4590
Iliopoulou, E.G., et al. (2010) A Phase I Trial of Adoptive Transfer of Allogeneic Natural Killer Cells in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Immunology, Immunotherapy, 59, 1781-1789. https://doi.org/10.1007/s00262-010-0904-3
Ferrara, J.L., et al. (2009) Graft-versus-Host Disease. The Lancet, 373, 1550-1561. https://doi.org/10.1016/S0140-6736(09)60237-3
Berraondo, P., et al. (2019) Cytokines in Clinical Cancer Immunotherapy. British Journal of Cancer, 120, 6-15. https://doi.org/10.1038/s41416-018-0328-y
Lotze, M.T., et al. (1981) Lysis of Fresh and Cultured Autologous Tumor by Human Lymphocytes Cultured in T-Cell Growth Factor. Cancer Research, 41, 4420-4425.
Mu, Y.X., et al. (2019) A Simple Method for in Vitro Preparation of Natural Killer Cells from Cord Blood. BMC Biotechnology, 19, 80. https://doi.org/10.1186/s12896-019-0564-0
Kang, L., et al. (2013) Characterization and ex Vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy. Frontiers in Immunology, 4, 101. https://doi.org/10.3389/fimmu.2013.00101
Geller, M.A., Cooley, S., Judson, P.L., Ghebre, R., Carson, L.F., Argenta, P.A., Jonson, A.L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., Dusenbery, K., Bliss, R., et al. (2011) A Phase II Study of Allogeneic Natural Killer Cell Therapy to Treat Patients with Recurrent Ovarian and Breast Cancer. Cytotherapy, 13, 98-107. https://doi.org/10.3109/14653249.2010.515582
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J. and Klingemann, H. (2008) Infusion of the Allogeneic Cell Line NK-92 in Patients with Advanced Renal Cell Cancer or Melanoma: A Phase I Trial. Cytotherapy, 10, 625-632. https://doi.org/10.1080/14653240802301872
Krause, S.W., Gastpar, R. andreesen, R., Gross, C., Ullrich, H., Thonigs, G., Pfister, K. and Multhoff, G. (2004) Treatment of Colon and Lung Cancer Patients with ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells: A Clinical Phase I Trial. Clinical Cancer Research, 10, 3699-3707. https://doi.org/10.1158/1078-0432.CCR-03-0683
Sutlu, T. and Alici, E. (2009) Natural Killer Cell-Based Immunotherapy in Cancer: Current Insights and Future Prospects. Journal of Internal Medicine, 266, 154-181. https://doi.org/10.1111/j.1365-2796.2009.02121.x
Melder, R.J., Whiteside, T.L., Vujanovic, N.L., Hiserodt, J.C. and Herberman, R.B. (1988) A New Approach to Generating Antitumor Effectors for Adoptive Immunotherapy Using Human Adherent Lymphokine-Activated Killer Cells. Cancer Research, 48, 3461-3469.
Whiteside, T.L., Wang, Y.L., Selker, R.G. and Herberman, R.B. (1988) In Vitro Generation and Antitumor Activity of Adherent Lymphokine-Activated Killer Cells from the Blood of Patients with Brain Tumors. Cancer Research, 48, 6069-6075.
Vujanovic, N.L., Rabinowich, H., Lee, Y.J., Jost, L., Herberman, R.B. and Whiteside, T.L. (1993) Distinct Phenotypic and Functional Characteristics of Human Natural Killer Cells Obtained by Rapid Interleukin 2-Induced Adherence to Plastic. Cellular Immunology, 151, 133-157. https://doi.org/10.1006/cimm.1993.1227
Alici, E., Sutlu, T., Bjorkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H.C., Gahrton, G., Ljunggren, H.G. and Dilber, M.S. (2008) Autologous Antitumor Activity by NK Cells Expanded from Myeloma Patients Using GMP-Compliant Components. Blood, 111, 3155-3162. https://doi.org/10.1182/blood-2007-09-110312
Parkhurst, M.R., Riley, J.P., Dudley, M.E. and Rosenberg, S.A. (2011) Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells But Does Not Mediate Tumor Regression. Clinical Cancer Research, 17, 6287-6297. https://doi.org/10.1158/1078-0432.CCR-11-1347